Vivo Capital, LLC Q1 2016 Filing
Filed May 16, 2016
Portfolio Value
$398.7B
Holdings
24
Report Date
Q1 2016
Filing Type
13F-HR
All Holdings (24 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris therapeutics | 4,191,397 | $79.4B | 19.92% | |
| 2 | —Sagent Pharmaceuticals, Inc. | 6,499,737 | $79.1B | 19.84% | |
| 3 | —Biotie Therapies Corp. | 1,220,234 | $32.5B | 8.16% | |
| 4 | —Nabriva Therapeutics AG | 3,151,700 | $28.2B | 7.08% | |
| 5 | CLDNEUREiger BioPharmaceuticals | 1,599,592 | $26.8B | 6.73% | |
| 6 | ASNDAscendis Pharma | 1,419,332 | $26.3B | 6.60% | |
| 7 | CDXSCodexis, Inc. | 5,573,319 | $17.3B | 4.35% | |
| 8 | —ProNAi Therapeutics, Inc. | 2,438,270 | $16.4B | 4.12% | |
| 9 | —Advanced Accelerator Applications S.A. | 455,798 | $16.0B | 4.00% | |
| 10 | —Agile Therapeutics, Inc. | 2,019,955 | $12.5B | 3.15% | |
| 11 | RGNXRegenxbio Inc. | 990,449 | $10.7B | 2.68% | |
| 12 | —Trevena, Inc. | 1,200,000 | $9.9B | 2.49% | |
| 13 | —Capnia, Inc. | 7,466,352 | $8.9B | 2.23% | |
| 14 | —Kite Pharma, Inc. | 193,193 | $8.9B | 2.22% | |
| 15 | —Akari Therapeutics Plc | 527,842 | $7.4B | 1.85% | |
| 16 | DVAXDynavax Technologies Corporation | 357,755 | $6.9B | 1.73% | |
| 17 | MEIPUSDMEI Pharma, Inc. | 2,767,718 | $3.5B | 0.87% | |
| 18 | —Carbylan Therapeutics | 4,204,562 | $2.7B | 0.67% | |
| 19 | CCXIEURChemoCentryx, Inc. | 887,906 | $2.2B | 0.55% | |
| 20 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $1.9B | 0.47% | |
| 21 | —Ocera Therapeutics, Inc. | 153,331 | $451.0M | 0.11% | |
| 22 | —Zosano Pharma Corp | 98,515 | $227.0M | 0.06% | |
| 23 | —Capnia, Inc. | 932,910 | $215.0M | 0.05% | |
| 24 | —Palatin Technologies, Inc. | 234,909 | $127.0M | 0.03% |